Details of the Drug Combinations

General Information of This Drug (ID: DM7GCVW)

• Drug Name: Acalabrutinib (DM7GCVW)
• Synonyms: Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326

Indication

leukaemia; ICD 11: 2A60-2B33; Status: Approved [1]; Mantle cell lymphoma; ICD 11: 2A85.5; Status: Approved [2]; Chronic lymphocytic leukaemia; ICD 11: 2A82.0; Status: Phase 3 [3]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 2 [4]

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acalabrutinib + Marizomib	DC1QMDY	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Alpelisib + Acalabrutinib	DC358A7	Alpelisib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Everolimus + Acalabrutinib	DCODIQS	Everolimus	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Idelalisib + Acalabrutinib	DCXVNC5	Idelalisib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
OSI-027 + Acalabrutinib	DCB26XH	OSI-027	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
RTB101 + Acalabrutinib	DC3LEMX	RTB101	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Sirolimus + Acalabrutinib	DC74571	Sirolimus	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]

10 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acalabrutinib + Acalabrutinib	DCXT5OW	Acalabrutinib	Pharmacokinetics	[6]
Acalabrutinib + Rabeprazole	DCDKVH4	Rabeprazole	Infectious Disease	[7]
Acalabrutinib + Thiotepa	DCTO5NB	Thiotepa	Refractory and Relapsed Primary CNS Lymphoma	[8]
Acalabrutinib + Bay 80-6946	DC02PGU	Bay 80-6946	Chronic Lymphocytic Leukemia (CLL)	[9]
Acalabrutinib + Isavuconazole	DCL5V3J	Isavuconazole	Central Nervous System Lymphoma	[10]
Lenalidomide + Acalabrutinib	DCS2BKF	Lenalidomide	B-cell Lymphoma	[11]
Acalabrutinib + Zanubrutinib	DC4Q6ZY	Zanubrutinib	Lymphoma, Mantle-Cell	[12]
Acalabrutinib + Venetoclax	DC04QN3	Venetoclax	Chronic Lymphocytic Leukemia	[13]
Acalabrutinib + Ibrutinib	DC9I6MQ	Ibrutinib	Chronic Lymphocytic Leukemia	[14]
Acalabrutinib + Venetoclax	DCMHUZ1	Venetoclax	Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	[15]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT04435483) A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
• [7] ClinicalTrials.gov (NCT04489797) A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
• [8] ClinicalTrials.gov (NCT05021770) Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
• [9] ClinicalTrials.gov (NCT04685915) Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
• [10] ClinicalTrials.gov (NCT04548648) A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
• [11] ClinicalTrials.gov (NCT05014100) Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
• [12] ClinicalTrials.gov (NCT04662255) Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
• [13] ClinicalTrials.gov (NCT03836261) Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
• [14] ClinicalTrials.gov (NCT06136559) A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
• [15] ClinicalTrials.gov (NCT05057494) A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma